Observational studyDrug design, development and therapy2026
Combined Double-Filtration Plasmapheresis and Corticosteroids are Associated with Improved Outcomes in Acute Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: An Ambispective Multicenter Cohort Study.
Observational study in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Double-filtration plasmapheresis (DFPP) and intravenous methylprednisolone (IVMP) are established treatments for acute myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) attacks, but comparative efficacy data remain limited. This study aimed to compare the efficacy between IVMP monotherapy and DFPP+IVMP therapy in acute MOGAD and identify factors associated with treatment response. Methods: Patients with acute MOGAD attacks receiving DFPP+IVMP or IVMP alone were enrolled in the ambispective, multicenter cohort study. Primary outcome was change in Expanded Disability Status Scale (EDSS) score. Secondary outcome included absolute EDSS and modified Rankin Scale (mRS) score, the change in mRS, improvement rates of EDSS and mRS, immunological parameters, and adverse events. Results: 36 MOGAD patients were enrolled (DFPP+IVMP: 15; IVMP: 21). At 3-month follow-up (3M-FU), the DFPP+IVMP group showed greater EDSS reduction [2.00 (1.00, 2.00) vs 1.00 (0.75,1.75), p=0.012] and mRS reduction [2.00 (1.00, 3.00) vs 1.00 (1.00,1.50), p=0.009] compared with IVMP alone. In the IVMP group, higher baseline EDSS score correlated with greater EDSS improvement ( Conclusion: DFPP+IVMP was associated with better functional recovery at 3M-FU compared to IVMP group for acute MOGAD, particularly in patients with high baseline serum IgG, and early intervention was important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.